BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

BK Virus in Salivary Gland Disease

The purpose of this study is to analyze BK viral infection in salivary gland diseases; specifically, to determine a definitive relationship between BK Virus and HIV associated salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1 to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days. Salivary function/protein secretion will be correlated with BK polyomavirus titers. It is expected that patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will benefit from Ciprofloxacin.

The study duration is 12 weeks with a baseline visit, a visit at 4 weeks and a visit at 12 weeks. At baseline participants are randomized to Ciprofloxacin or placebo and take the drug or placebo for 28 days. At subsequent visits BK polyomavirus presence and salivary gland function will be assessed.

Inclusion Criteria:

• HIV positive with Salivary Gland Disease
• Ability to read and understand English

Exclusion Criteria:

• Allergy to the family of fluoroquinolones (including ciprofloxacin)
• Currently taking tizanidine
• Concurrently taking antiacids containing magnesium hydroxide or aluminum hydroxide
• Current use of Theophylline
• Previous tendon disorder such as Rheumatoid arthritis
• History of seizures
• Current use of phenytoin
• Current use of glyburide
• Current use of methotrexate
• Severe renal impairment (known creatinine clearance < 30 or on dialysis)